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A B S T R A C T
Activated macrophages play a central role in both the development and resolution of inflammation. These
immune cells need to be functional in harmful conditions with high levels of reactive oxygen and nitrogen
species that can damage their basic cell components, which may alter their metabolism. An excessive accu-
mulation of these cell alterations drives macrophages inexorably to cell death, which has been associated to the
development of several inflammatory diseases and even with aging in a process termed as “immunosenescence”.
Macrophages, however, exhibit a prolonged survival in this hostile environment because they equip themselves
with a complex network of protective mechanisms. Here we provide an overview of these self-defense me-
chanisms with special attention being paid to bioactive lipid mediators, NRF2 signaling and metabolic repro-
gramming.
1. The dual role of macrophages during inflammation and
resolution of inflammation: role of reactive oxygen and nitrogen
species
Macrophages (ΜΦs) are part of the innate immune system and can
differentiate into several subtypes with opposite functions in the course
of the immune and inflammatory response [1–3]. Their activation plays
a central role in both innate and acquired immunity, which suggests a
tightly regulated switch in response to environmental conditions that
promote ΜΦ recruitment via tissue infiltration. The high plasticity of
ΜΦs enables these cells to respond and adapt to the specific require-
ments of the inflamed area [1,4,5]. The functions of ΜΦs include host
defense against pathogens, phagocytosis and pathogen killing, bone
dynamics, antigen presentation, local inflammatory reactions, wound
healing, blood lipid homeostasis and tissue remodeling [6–8].
In the course of activation by pathogens and other pathophysiolo-
gical triggers, ΜΦs express specific sets of genes (e.g. pro-inflammatory
cytokines, chemokines and matrix metalloproteinases) that support the
initiation of the host defense against these challenges. This initial action
is followed by the sequential release of mediators that govern the
progression from the early cell-aggressive steps to tissue repair, deac-
tivation of the initial pro-inflammatory response and resolution of the
aggression process [9–12]. ΜΦs are very active in synthesizing, pro-
cessing, and releasing a plethora of bioactive molecules, including
prostaglandins, leukotrienes, and other classic eicosanoids that exhibit
pro-inflammatory functions; bioactive lipids with anti-inflammatory or
pro-resolution activities; and matrix metalloproteinases that accom-
plish tissue remodeling [13–15]. Reactive oxygen and nitrogen species
(ROS and RNS, respectively) are also prototypical ΜΦ mediators that
play a central role in effector functions (Fig. 1). ΜΦs increase ROS and
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RNS production after exposure to a number of different signals in-
cluding pathogen-derived or damage associated molecular patterns
(PAMPs, such as lipopolysaccharide or DAMPs, such as high-mobility
box 1 protein, nucleotides, and DNA, respectively), cytokines (e.g.
TNFα, IFNγ), metabolic stress (e.g. hyperglycemia, advanced glycation
endproducts, oxidized lipoproteins), endoplasmic reticulum stress, un-
folded protein accumulation (unfolded protein response; UPR), and
various nanoparticles. This exacerbated release of ROS and RNS con-
stitutes the oxidative burst: a defense mechanism initiated by ΜΦs to
destroy pathogens thanks to the bactericidal activity of ROS and RNS.
The most important sources of ROS in activated ΜΦs are NADPH
oxidase 2 (NOX2), xanthine oxidase (XO), and the mitochondrial elec-
tron transport chain. Superoxide (O2●-), and hydrogen peroxide (H2O2)
generated by these systems play signaling roles, but may also contribute
to cell dysfunction and death [16,17]). Superoxide is formed by one-
electron reduction of molecular oxygen [18] as catalyzed by NOX or XO
enzymes or by the mitochondrial electron transport system. Normally,
electrons are transferred through mitochondrial electron transport
chain to reduce dioxygen by four electrons, but approximately 1–3% of
all electrons leak from the system and produce superoxide [18,19].
Superoxide is converted to H2O2 by the action of superoxide dismutases
(SODs). Peroxisomal reactions mediated by oxidant enzymes also re-
present a source of H2O2 [20]. In the presence of Fe2+ ions, hydrogen
peroxide can be broken down to hydroxyl radicals (●OH) in a complex
process known as Fenton reaction. Hydroxyl radical is the most reactive
ROS and can damage proteins, lipids, carbohydrates and DNA con-
tributing to cell dysfunction and death [21].
In addition to direct DNA damage, ROS can influence the “methy-
lome” through the formation of oxidized DNA lesions with structural
similarities to epigenetic signals. Furthermore, they can indirectly
modulate the activity of the epigenetic machinery, indicating that
epigenetic changes are tightly linked to cellular metabolism and energy
levels. All these alterations have been strongly associated with aging
and longevity leading to subclinical accumulation of im-
munosenescence factors. This fact has been suggested to contribute to
various diseases in the elderly [22–24].
Nitric oxide (NO) represents the most predominant form of RNS
synthesized by ΜΦs and is a major signaling radical capable of mod-
ulating various functions as well as viability of ΜΦs. Elevated NO
synthesis in activated pro-inflammatory ΜΦs is one of the main cyto-
static, cytotoxic, and pro-apoptotic mechanisms participating in the
innate immune response, at least in non-primate species [25]. ΜΦs
express all three NO synthase (NOS) isoforms. Transcriptionally regu-
lated NOS2 (inducible NOS; NOS2) can produce large amounts of NO
for prolonged periods of time while the activity-regulated constitutive
isoforms NOS1 (neuronal NOS) and NOS3 (endothelial NOS) respond
rapidly to calcium signals [26]. While the role of NOS2 in the anti-
microbial activity of ΜΦs is well known [26], NOS1 is required for ΜΦ
uptake of LDL during foam cell formation [27] and NOS3 may con-
tribute to the initiation of the immune response [28]. In humans, spe-
cial mention is required for the expression of NOS2 by activated pro-
inflammatory ΜΦs. Despite the high homology of the Nos2/NOS2 gene
across mammalian species, the promoter region varies substantially in
primates, which explains the poor inducibility of the gene in humans
[4,25,29–31]. This situation is perhaps responsible for the development
of survival strategies by several pathogens, such as trypanosomes that
cannot be efficiently cleared from infected human ΜΦs (Fig. 2). Ab-
sence of NO synthesis as it happens in higher mammals restricts the
oxidative burst of ΜΦs to superoxide and hydrogen peroxide produc-
tion only.
When NO is present in mitochondria either by mitochondrial NOS
action or by diffusion from vicinal compartments, it can react with
superoxide to yield peroxynitrite (ONOO−) in situ [32].This is a rapid
reaction (in fact, one of the fastest reactions in nature, not catalyzed by
enzymes) that produces a potent oxidant, more reactive than its pre-
cursors. In addition to the nitration (mainly in tyrosine residues) of a
large number of proteins, peroxynitrite can also oxidize amino acid
residues essential for the function of many proteins, including tran-
scription factors and enzymes [33]. In DNA, ONOO− can induce strand
Fig. 1. Mechanisms of reactive oxygen and nitrogen species generation in
macrophages. ROS are generated via enzymatic reactions mediated by NADPH
oxidase 2 (NOX2) and xanthine oxidase (XO) and/or as a result of mitochon-
drial respiratory dysfunction. RNS production is mainly driven by NOS2, whose
main product, NO, has either pro- or anti-apoptotic and survival functions,
depending on the generation rate. Both ROS and RNS dramatically affect cell
metabolism, DNA integrity, and macrophage viability.
Fig. 2. Differences in the regulatory elements
of the NOS2 gene promoter among mammals.
The decrease in pro-inflammatory-triggered NO
production in primates lies in the lack of several
motifs in the NOS2 gene promoter, which con-
fers a restrictive transcriptional regulation of the
gene and, therefore, limits the capacity of cells
to accomplish high-output synthesis of NO.
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breaks and base modifications (e.g. 8-nitroguanine formation) [34].
Pro-inflammatory ΜΦs can survive for several days under the
stressful environment of highly reactive molecules due to their high
metabolic plasticity [1]. Uniquely, NO synthesis by ΜΦs leads to a
hyperpolarization of the mitochondria, which preserves mitochondrial
activity for a while, preventing the release of cytochrome c and other
mitochondrial-dependent pro-apoptotic mediators [31]. In addition,
mediators such as p53 are highly over-expressed to prevent DNA da-
mage and extend the functional activity of ΜΦs [35]. Moreover, most
physiological ΜΦ functions, such as phagocytosis, require preservation
of cell integrity, mainly through attenuation of the auto-apoptotic re-
sponse. Indeed, NO plays a dual role, favoring cell viability or inducing
apoptotic/necrotic death depending on the cell type and the amount of
NO produced [36,37]. Thus, moderate NO synthesis can inhibit apop-
tosis in several cell types including B lymphocytes and hepatocytes
[36,38]. Several targets have been identified in this protective me-
chanism mediated by NO, including caspase regulation and the ex-
pression of antiapoptotic genes from the inhibitor of apoptosis protein
(IAP) family [39]. Caspase processing and activation are inhibited due
to the formation of NO-adducts with the cysteine residues present in the
catalytic domain of these enzymes via transient S-nitrosylation reac-
tions [40]. Indeed, S-nitrosylation of cysteine residues (for example, in
GSH) yielding nitrosothiols is one of the mechanisms that prolong the
bioactivity of NO since nitric oxide can be released from nitrosothiols
for longer periods of time in a subcellular compartment specific
manner. Interestingly, in vitro treatment of ΜΦs with chemical NO
donors (which rapidly decompose and release high amounts of NO into
cells) promote apoptosis, as confirmed by sequential activation of cas-
pase 9 and 3, loss of plasma membrane asymmetry and DNA frag-
mentation. However, the kinetics of this process is very dependent on
the rate of NO generation. A sustained, moderate release of NO re-
sembling the in vivo response (e.g. that generated by DETA-NONOate;
half-life ca. 10 h), induces a significantly reduced apoptotic response
[41,42]. The presence of modest levels of NO reduces apoptosis by
maintaining higher levels of anti-apoptotic proteins and inhibiting the
activity of caspases.
2. The role of functional state of macrophages in determining
sensitivity to ROS and RNS
ΜΦs are highly plastic cells with a rapidly changing phenotype in
response to altered microenvironment. In a very simplistic way, two
principal polarization states have been described, M1 or classically
activated macrophages, and M2 or alternatively activated macro-
phages. M1ΜΦs exhibit a pro-inflammatory response inducing a robust
anti‐microbial and anti‐tumoral activity and M2 ΜΦs promote tissue
repair and wound healing. Exposure to cytokines, chemokines, toxins,
PAMPs and DAMPscan dramatically shape the functional state and
oxidative stress sensitivity of these cells. Despite their high resistance to
ROS, ΜΦs are still not fully resistant to ROS-induced death. In fact,
when oxidative stress is maintained for long period of time, ΜΦs ac-
cumulate massive amounts of oxidized proteins and lipids, leading to
metabolic dysfunction. In more advanced stages, the loss of DNA in-
tegrity leads to an inevitable cell death. Recently Regdon et al. [43]
investigated the mechanisms whereby ΜΦs develop a high degree of
resistance against oxidative stress. In their experiments, an exogenous
ROS (H2O2) was used to simulate the oxidative microenvironment in
order to elucidate the cell death modality of these H2O2-treatedΜΦs. In
this model, ΜΦs were treated with high concentrations of H2O2 to
elucidate the cell death modality in response to ROS. ΜΦs exposed to
high concentrations of H2O2 underwent regulated necrotic cell death
similar to parthanatos. Parthanatos is a form of programmed necrotic
cell death [44] triggered by severe DNA damage and mediated by the
activation of the DNA damage response enzyme, poly(ADP-ribose)
polymerase-1 (PARP1) [108].
Interestingly, the functional state of ΜΦs had been related to dif-
ferential susceptibility of M1 or M2 to cell death. For example, induc-
tion of matureΜΦs from BMDM (bone marrow-derivedΜΦs) by M-CSF
treatment caused increased H2O2 resistance. Subsequent exposure to
LPS, an inflammatory polarization signal (M1 stimulus), conferred
maximal protection to ΜΦs while IL-4 (M2 challenge) had no effect
[43]. An important question is how M1 polarization is linked to the
development of oxidative stress resistance. The mechanism underlying
H2O2 resistance of M1ΜΦs appears to be based on at least three pillars:
inhibition of cell death signaling, upregulation of antioxidant defense
and metabolic reprogramming [43]. Conversely, a recent report sug-
gests that in other cell contexts as lipotoxicity, the M2 phenotype can
confer protection to adipose-tissue resident ΜΦs enhancing their tol-
erance to lipid-mediated stress [45].
Inflammatory (e.g. LPS-treated) ΜΦs display a dramatically altered
gene expression landscape (Fig. 3). Part of the genetic reprogramming
in inflammatory ΜΦs involves cell death genes, such as Parp1. LPS-
induced downregulation of PARP1 expression in ΜΦs appears to be a
key factor renderingΜΦs resistant to oxidative stress. The expression of
PARP1 from a viral promoter, which is unresponsive to LPS-induced
suppressive signals, restores H2O2 sensitivity ofΜΦs, demonstrating the
importance of PARP1 suppression [43]. Moreover, the expression of
various antioxidant enzymes and proteins vary greatly in LPS-stimu-
lated cells. Interestingly, catalase and SOD1 expression decreased sig-
nificantly after treatment with LPS, while glutathione reductase,
thioredoxin reductase, and peroxiredoxin 1 expression increased [43].
These latter changes may play a role in oxidative stress resistance;
however, the most significant change could be observed in SOD2 ex-
pression, which increased approximately tenfold in LPS-treated cells.
Cells undergoing parthanatos have been shown to display secondary
mitochondrial superoxide production [46], and SOD2 silencing was
found to abolish the protective effects of LPS against H2O2 cytotoxicity
[47]. These results highlight the importance of SOD2 induction in the
Fig. 3. Oxidative stress resistance in LPS-treated (M1/pro-inflammatory)
macrophages. Severe oxidative DNA damage induces activation of the nuclear
DNA nick sensor enzyme, PARP1. PARP1 is the central mediator of the
PARylation-dependent cell death route, termed parthanatos. LPS induces M1
differentiation in macrophages via TLR4. Additionally, this stimulation triggers
downregulation of PARP1, induction of SOD2 and other antioxidant proteins,
and promotion of metabolic reprogramming favoring glycolysis. As a result, cell
death pathways, especially parthanatos, become highly inhibited.
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development of oxidative stress resistance of M1ΜΦs. Interestingly, the
roles of PARP1 and SOD2 appear to be interconnected as PARP1 par-
ticipates in the regulation of Sod2 gene expression [47]. This regulation
is complex and has been suggested to involve a functional interplay
between PARP1 and the lysine-specific histone demethylase 1A (LSD1)
(for details see Ref. [47]).
The role of metabolic regulation in various cellular functions, in-
cluding the sensitivity of ΜΦs to toxic stimuli, has been increasingly
recognized. The high plasticity of ΜΦs involves dynamic metabolic
reprogramming to adjust their metabolism to their functional state. M1
ΜΦs operate a glycolytic metabolism similar to the Warburg phenotype
(aerobic glycolysis) of cancer cells [5,43,48–50]. While the rationale for
this metabolic shift in cancer cells has been a subject of heated debates,
its contribution to a resistant phenotype is widely acknowledged. Par-
thanatos resistance in LPS-stimulated ΜΦs is associated with the War-
burg phenotype [47] through the following possible mechanisms: a) a
shift from oxidative to glycolytic metabolism, which prepares cells for
the consequences of oxidant-induced damage to mitochondrial re-
spiration; b) downregulation of mitochondrial activity, which limits
mitochondrial ROS production; c) rapidly inducible glycolytic ATP
production, which may be beneficial in ATP depletion scenarios (e.g.
PARP1 over-activation) [10,51]; and d) a glycolytic switch, which may
impact epigenetic reprogramming to influence the regulation of cell
death and antioxidant enzymes [10]. One must be cautious, however,
when translating murine data to human settings as murine and human
ΜΦs show fundamental differences in LPS-induced metabolic repro-
gramming and RNS synthesis [12,25].
3. Molecular mechanisms of self-protection in macrophages
The high amount of ROS and RNS produced inside ΜΦs to defend
from pathogens requires the existence of protective mechanisms against
this oxidative burst to ensure ΜΦ survival during the inflammatory
process. Although the specific mechanisms for ROS sensing and
scavenging within ΜΦs remain elusive [52], recent reports inicate that
these cytoprotective mechanisms may be acquired during differentia-
tion from monocytes [53]. In fact, the lack of antioxidant mechanisms
in monocytes is thought to establish a negative feedback loop where
ROS produced by ΜΦs kill monocytes to avoid an exaggerated in-
flammatory response [53].
The nuclear factor erythroid 2-related factor 2 (NRF2) pathway
represents the main strategy to alleviate oxidative stress in ΜΦs
[54–56] (Fig. 4). NRF2 belongs to the cap ‘n’ collar (CNC) subfamily of
basic-region leucine zipper (bZIP) transcription factors. When stable,
NRF2 translocates to the nucleus and binds to antioxidant response
elements (AREs) to upregulate genes implicated in metabolism, pro-
teostasis and redox balance [55,57]. NRF2 target genes include heme-
oxygenase 1 (Hmox1) and ferritin complex (Ftl and Fth), which prevent
hydroxyl radical production by releasing Fe2+ from heme molecules
and oxidizing Fe2+ to Fe3+, respectively. NRF2 also targets the ex-
pression of both subunits of the glutamate-cysteine ligase complex (Gclc
and Gclm), which participate in glutathione synthesis [57]. Other tar-
gets of NFR2 include glutathione peroxidase 2 (Gpx2), glutathione re-
ductase 1 (Gsr1), and several glutathione-S-transferases (Gsta1-3, Gsta5,
Gstm1-3 and Gstp1), which are involved in glutathione redox cycle.
NRF2 also regulates the expression of thioredoxin reductase 1 (Txnrd1)
and sulfiredoxin 1 (Srxn1), which reduce protein thiols [57]. Finally,
NRF2 also targets NAD(P)H:quinone oxidoreductase 1 (Nqo1), which
reduces reactive quinones to less toxic hydroquinones [58].
To appropriately bind to AREs, NRF2 first needs to form a stable
complex with members of the small masculoaponeurotic fibrosarcoma
(sMAF) family of proteins (MAFF, MAFG and MAFK) [57,59]. In fact,
disruption of the NRF2-sMAF complex by deletion of both MAFF and
MAFG was shown to inhibit NRF2 signaling [57,59]. In addition to the
induction of the antioxidant response, NRF2 signaling actively inhibits
the pro-inflammatory response independently of ROS and ARE in ΜΦs,
supporting the cytoprotective role of the NRF2 pathway [60].
To ensure the appropriate control of the antioxidant and anti-in-
flammatory responses, a tightly regulated protein network maintains
low levels of NRF2 under unstressed conditions [59]. The main NRF2
regulator is Kelch-like ECH-associated protein 1 (KEAP1), a protein
constitutively expressed in cells. KEAP-1 homodimerizes and binds to
cullin 3 (CUL3) to form the KEAP1-CUL3 ubiquitin ligase complex. This
complex catalyzes the polyubiquitination of NRF2 to induce its pro-
teasomal degradation [59]. Most inducers of the NRF2 pathway inhibit
KEAP1 function by preventing its dimerization through targeting of
cysteine thiol residues (sulforaphane, bardoxolone), by inhibiting its
association with NRF2 (tert-butylhydroquinone) or by promoting the
dissociation of NRF2 from the ubiquitin ligase complex (As3+, Cd2+,
and Cr6+) [59]. In addition to KEAP1-associated polyubiquitination,
NRF2 can be regulated through other mechanisms that promote its
nuclear import/export or degradation, including phosphorylation/de-
phosphorylation or acetylation/deacetylation. In addition, several mi-
croRNAs target Nrf2 and Keap1 mRNA to repress or induce the NRF2
pathway, respectively [59].
The exacerbation of oxidative damage in ΜΦs and the aggravation
of inflammatory diseases upon NRF2 deficiency have been widely de-
scribed in the literature [54,56]. Interestingly, the role that NRF2 plays
in foam cells during atherogenesis remains unclear as conflicting data
in the literature report both protective and deleterious functions [60].
In contrast, NO is capable of triggering an adaptive response to oxi-
dative stress in pro-inflammatory ΜΦs by inducing the NRF2 pathway
[61]. Recently, the work of Wang et al. revealed that MTS1 and MTS2,
two kinases implicated in cell growth, polarity, migration and apop-
tosis, induce the NRF2-associated antioxidant response by phosphor-
ylating and inactivating KEAP1 in BMDM [52]. Interestingly, MTS1/2
have been previously implicated in ROS trafficking from mitochondria
Fig. 4. Antioxidant mechanism of the NRF2 pathway. Under basal condi-
tions, the NRF2 transcription factor is sequestered and polyubiquitinated by the
KEAP1/CUL3 complex, ensuring its degradation. ROS are able to inhibit this
association, leading to NRF2 stabilization and accumulation. NRF is then
translocated into the nucleus where it upregulates a series of genes involved in
the antioxidant response. The NRF2-KEAP1/CUL3 complex can also be desta-
bilized by antioxidant molecules, metabolites (e.g. itaconate), and even by
autophagic mediators, whereas NO production may induce the NRF2 pathway
as an adaptive response.
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to phagosomes as part of the TLR signaling cascade [62]. Along the
same lines, heme oxygenase (HO) has been found to indirectly enhance
phagocytic activity in ΜΦs by diminishing intracellular heme levels as
part of the antioxidant response, strengthening the bactericidal function
[63]. Altogether, these results indicate that NRF2 pathway plays a
critical role in ΜΦ self-protection against oxidative damage by finely
regulating both ROS generation and detoxification. Thus, these im-
portant pathways should be further investigated.
Another canonical antioxidant pathway is the FOXO pathway,
which is comprised of four different transcription factors: FOXO1,
FOXO3, FOXO4, and FOXO6. The FOXO transcription factors bind to
specific DNA motifs (DBEs, DAF-16 family member-binding elements)
to induce the expression of target genes, including MnSOD and catalase
[64]. Apart from defending against ROS, FOXO pathway is also im-
plicated in cell cycle arrest, apoptosis, differentiation and DNA repair
[65]. In the immune system and particularly in ΜΦs, the role of the
FOXO pathway remains controversial. Some reports indicate that
FOXO3 is predominantly expressed in myeloid cells, including ΜΦs,
whereas others did not detect any expression of either FOXO1 or
FOXO3 [52,65]. Interestingly, in ΜΦs FOXO1 has been found to sti-
mulate both pro- and anti-inflammatory pathways by upregulating the
Tlr4 gene and the IL-10 promoter, respectively [66,67]. The simulta-
neous deletion of FOXO1, 3 and 4 induces monocytosis and increased
NOS2 expression and oxidative stress in mice [68]. These data highlight
the versatility of functions and the complexity of the FOXO interaction
network, which has not been completely elucidated yet in the context of
ΜΦ oxidative stress and inflammation.
Supporting these two major antioxidant pathways, additional cy-
toprotective mechanisms such as autophagy [69], UPR [70], and the
hypoxia-inducible factor 1 (HIF1) pathway [71], also orchestrate the
elimination of ROS and RNS to alleviate oxidative damage. Autophagy
includes several processes that drive the degradation of different dys-
functional cytoplasmic components inside autophagosomes in order to
recycle nutrients upon starvation or other stressful conditions affecting
cellular homeostasis, such as oxidative stress [69]. During infections,
ΜΦs engulf pathogens to form phagosomes that are subsequently tar-
geted by autophagic proteins (e.g. p62 and NDP52) to form autopha-
gosomes, where oxidative burst takes place [72]. This process has been
found to be dependent on ROS production by NOX2, since the inhibi-
tion or deletion of this enzyme impairs the recruitment of autophagic
components and hence autophagosome formation [73]. Interestingly,
p62 is also able to induce NRF2 pathway by degrading KEAP1 via au-
tophagy (Fig. 4) [74]. Therefore, autophagy provides a compartment
that confines ROS production and prevents pathogen escape while sti-
mulating antioxidant pathways to counterbalance this oxidative burst
[69].
UPR is induced to alleviating endoplasmic reticulum stress gener-
ated by aberrant protein accumulation elicited in oxidative stress si-
tuations [70]. Specific mediators of the UPR (XBP1 and IRE1) are ac-
tivated inΜΦs upon TLR signaling. This activation is dependent on ROS
production by NOX2 [74]. As a result, a non-canonical UPR signaling
pathway is triggered contributing to enhance the inflammatory re-
sponse by activating both Il6 and Tnf genes and reducing endoplasmic
reticulum stress within an oxidative burst context [70,74]. There is a
crosstalk between UPR and the aforementioned NRF2 and FOXO anti-
oxidant pathways, which provides yet another defense mechanism to
fight against ROS and RNS overproduction under ER stress conditions
[75,76].
The HIF1 pathway is initiated by the HIF1α subunit. When stimu-
lated, the HIF1α subunit becomes stable and associates with the HIF1β
constitutive subunit to form a HIF1 transcription factor complex. The
HIF1 transcription factor complex translocates to the nucleus and up-
regulates a series of genes involved in hypoxia resistance and metabolic
switch [71]. Oxidative stress is a well-known inductor of HIF1 pathway
in pro-inflammatory ΜΦs, ROS induction of the HIF pathway is re-
sponsible for the metabolic change towards glycolysis [71]. As a result,
mitochondrial respiration is attenuated and ROS production dramati-
cally decreases [77]. Interestingly, this metabolic switch also causes the
accumulation of citrate produced in Krebs cycle, which increases NOX2
and NOS2 activity [77]. Altogether, these data suggest that upon sti-
mulation, HIF1 pathway efficiently diminishes oxidative stress gener-
ated by mitochondria while promoting inherent ROS and RNS pro-
duction mechanisms of the inflammatory response in ΜΦs.
The natural resistance-associated macrophage proteins (NRAMPs), a
group of secondary carrier proteins that are involved in metal ion
transport (i.e. Mn2+/Fe2+ and H+ antiporters) [78] may also con-
tribute to ΜΦ self defense. These proteins are highly conserved across
evolution and their loss of function not only reduces the inflammatory
response to infection, but also promotes iron recycling by macrophages.
Iron is used by cells to support electron exchanges in core biological
processes, such as ATP production and mitochondrial electron transport
chain, and to transport oxygen and other gases by hemoglobin [79].
Release of high amounts of heme upon red blood cell (RBC) senescence
or damage increases iron cytotoxicity, eventually leading to a specific
form of programmed cell death termed ferroptosis [80]. A specific
macrophage subset is capable of phagocytosing those RBCs [81], me-
tabolizing heme groups and recycling the iron back to erythroid pro-
genitors [81]. NRAMPs can increase HO-1 levels [82], which in turn
can also modulate NOX2 expression and activity [83] and generates CO
that is cytoprotective [84], suggesting that heme catabolism by HO-1
can also protect macrophages from oxidative stress by modulating
NOX2.
Along with antioxidant and cytoprotective pathways that help re-
ducing the oxidative burden, ΜΦs can also make use of ascorbate (vi-
tamin C) and α-tocopherol (vitamin E). Concentrations of these two
ROS scavenger molecules depend on dietary intake [85]. Ascorbate is
able to scavenge a broad spectrum of free radicals, including super-
oxide, hydroxyl, aqueous peroxyl and alkoxyl radicals. Ascorbate also
neutralizes protein hydroperoxides [85]. In ΜΦs, treatment with as-
corbate was shown to alleviate oxidative stress and to improve pha-
gocytic activity whereas ablation of the ascorbate transporter increased
ROS susceptibility and apoptosis [86]. α-Tocopherol efficiently neu-
tralizes lipid peroxyl radicals [87], however, the antioxidant potential
of α-tocopherol is still under debate. Low levels of α-tocopherol are also
able to elicit lipid peroxidation reactions, which may explain the ne-
gative results obtained in clinical trials evaluating the effects of α-to-
copherol in myocardial infarction patients [88]. Lastly, the antioxidant
function of 7,8-dihydroneopterin should also be noted. 7,8-Dihy-
droneopterin is an intermediate of 5,6,7,8-tetrahydrobiopterin synth-
esis, the cofactor for NOS2, from GTP [87]. This synthesis is activated
mainly by interferons α/γ and LPS; however, in primateΜΦs these pro-
inflammatory stimuli do not increase the expression of 6-pyruvoylte-
trahydropterin synthase, the intermediary enzyme that metabolizes 7,8-
dihydroneopterin-triphosphate, leading to 7,8-dihydroneopterin accu-
mulation [87]. 7,8-Dihydroneopterin is able to scavenge free radicals
such as hydroxyl and peroxyl radicals, HOCl and oxLDL thus reducing
cellular oxidative stress, restoring thiol levels and inhibiting cell death
[87]. Nonetheless, 7,8-dihydroneopterin levels in activated ΜΦs have
not been completely determined nor have any strategies to increase
them been designed [87], demanding greater research in this field.
It should be emphasized that the importance of the mechanisms
listed above do not solely depend on their antioxidant potential, but
also on their interplay with pro-inflammatory and pro-resolving path-
ways, which is crucial for the appropriate balance between ΜΦ pro-
tection and inflammatory function [41,89].
4. Bioactive lipids, self-defense mechanisms and macrophage
resolution of inflammation
Lipids are not just the major constituents of cell membranes and
efficient sources of energy, but also can be key pathophysiological
mediators of several intercellular and intracellular processes. Indeed,
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endogenous lipids are one of the most important players in all phases of
inflammation, including the resolution phase [1,3,14,90,91]. This is the
reason why lipids are often called “bioactive lipids”. Lipids can be di-
vided into several families according to their biochemical functions: a)
classical eicosanoids with pro-inflammatory functions (e.g. pros-
taglandins, prostacyclins and thromboxanes); b) specialized pro-resol-
ving mediators (SPMs), which are considered pro-resolving lipids due to
their anti-inflammatory and pro-resolution functions (e.g. lipoxins, re-
solvins, protectins and maresins); c) lysoglycerophospholipids/sphin-
golipidis, structural membrane components that participate in several
signaling pathways; and d) endocannabinoids, which regulate nu-
merous cellular processes upstream of mechanisms that control cell and
tissue adaptation to inflammatory events. All lipid families are gener-
ated from essential ω-6 or ω-3 polyunsaturated fatty acid (PUFA) pre-
cursors that are esterified into membrane lipids. Bioactive lipids act by
binding to and activating specific G protein coupled receptors (GPCRs),
among other targets [92]. Since both pro-inflammatory and anti-in-
flammatory mediators are derived from the same precursors, the bal-
ance between pro- and anti-inflammatory products is crucial to main-
tain homeostasis and to prevent inappropriate inflammation.
In the course of inflammation, the innate immune cells rapidly
generate classical eicosanoids that are highly pro-inflammatory with
the aim of removing adverse stimuli. Their main role is the recruitment
of immune cells to the damaged area to initiate and amplify the in-
flammatory response. However, this process needs to be self-limiting
and, once the noxious stimulus has been controlled, the cellular sce-
nario changes to the “resolution of inflammation phase”, where the
same innate immune cells undergo a temporal lipid mediator class
switch and start producing bioactive ‘repair’ lipids: the SPMs. All of
these mediators originate from the same PUFAs (Fig. 5). Cis-linoleic
acid (LA) is metabolized to arachidonic acid (AA), whereas α-linolenic
acid (ALA) is converted to eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA).
To date, more than 20 different SPMs have been identified via so-
phisticated lipidomic approaches, although LXA4 and RvD1 are the
most studied SPMs so far [93]. These mediators are subdivided into six
main classes: AA-derived LXs (LXA4 and LXB4), EPA-derived E-series
resolvins (RvE1–3), DHA-derived D-series resolvins (RvD1–6), pro-
tectins, neuroprotectins (PD1/NPD1 and PDX), and maresins (MaR1
and MaR2). The clupanodonic (DPA)-derived 13-series resolvins
(RvT1–4) were also recently identified. SPMs actively terminate in-
flammation by reducing leukocyte infiltration and the recruitment and
stimulation of nonphlogistic mononuclear cells. This situation promotes
killing and clearance of pathogens via ΜΦ-mediated phagocytosis of
apoptotic granulocytes (efferocytosis) and cellular debris. At the same
time, the synthesis of pro-inflammatory cytokines is repressed, while
the accumulation of anti-inflammatory mediators shortens the time of
resolution and activation of endogenous resolution programs. Overall,
the result is the promotion of tissue regeneration and healing to restore
full tissue homeostasis. When inflammation is not properly ex-
tinguished, due to defective resolution, chronic inflammation develops,
which contributes to the development of a majority of prevalent
pathologies. Therefore, SPMs are considered key molecules with po-
tential therapeutic uses as STOP-inflammation signals.
During efferocytosis of apoptotic neutrophils, ΜΦs normally over-
come oxidative stress-induced apoptosis. ΜΦ death impairs the re-
solution process inducing a chronic inflammatory scenario. Thus, these
immune cells have to modulate their redox metabolism to favor their
own survival. In this sense, many groups have described how SPMs can
modulate the balance of the main antioxidant enzymes in several pa-
thological models reducing ROS levels in cells. Thus, it is known that
NRF2 and NOX2 levels are strictly balanced in ΜΦs and both can be
modulated by SPMs. Indeed, LXA4 reduces apoptosis and activates au-
tophagy in ΜΦs mainly via AKT and ERK. In addition, NRF2-dependent
transcriptional regulation is an auxiliary anti-oxidant mechanism
[15,91]. In fact, autophagy has been identified as part of the self-de-
fense mechanisms of myeloid cells [94]. Moreover, LXA4 improves the
phagocytic capacity of these immune cells, favoring the resolution of
inflammation. Lee et al. showed that RvD1 reduced ΜΦ apoptosis by
upregulating the levels of several anti-apoptotic proteins of the Bcl-2
family and inhibiting the activation of the pro-oxidant enzyme NOX2
[95]. Thus, SPMs in ΜΦs have a protective role, which prolongs their
viability and favor an antioxidant balance modulating both NRF2 and
NOX2 pathways. In the same context but in a different cell type, SPMs
are very effective in upregulating antioxidant defense mechanisms in
animal models. For example, an LXA4 derivative blocks ROS generation
in endothelial cells by suppressing NOX activity [96]. Furthermore, in a
murine model of cigarette smoke-induced emphysema, RvD1 is capable
of reducing inflammatory and oxidative markers in lungs, resulting in
improved pulmonary functions. These effects are associated with an
RvD1-mediated increase in SOD activity [97]. RvD1 also protects
against oxidative stress by decreasing LPS-induced synthesis of lipid
peroxides and malondialdehyde, and protects against glutathionyl-4-
hydroxy-trans-2-nonenal (GS-HNE)-initiated inflammation by in-
hibiting leukocyte infiltration [98]. RvD1 can also reduce UV-induced
skin oxidative stress by preventing UVB-elicited NRF2 downregulation
Fig. 5. Metabolic pathways of bioactive lipids production. While all pro-inflammatory classical eicosanoids (prostaglandins, thromboxanes, and leukotrienes)
derive from arachidonic acid metabolism, SPMs can either be synthesized from arachidonic acid (lipoxins) or from polyunsaturated fatty acids like EPA (E-series
resolvins) or DHA (D-series resolvins, protectins and maresins). The main enzymes implicated in these pathways are lipoxygenases and cyclooxygenases.
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and catalase inactivation, which lead to decreased hydroperoxides and
superoxide and maintained GSH levels [99]. Importantly, all SPM levels
in humans plasma, tissues or another biological fluids are in the pg to
ng/ml range [100–102]. These endogenous concentrations are
equivalent to the doses used in the broad majority of the studies where
their effects are described. This fact indicates that endogenous SPMs
can be active in the antioxidant scenario in a similar manner as exo-
genous analogs.
ROS and RNS can interact with several enzymes to modify their
functionality, which affects SPMs synthesis. In fact, ROS can activate
TLR4 receptors to promote the biosynthesis of RvD1 through the up-
regulation of lipoxygenase enzymes, particularly 12-LOX. Increased
RvD1 may also inhibit the nuclear translocation of 5-LOX in an auto-
crine manner. This creates a positive feedback loop for RvR1 synthesis
via the cytosolic interaction of 5-LOX with 12-LOX, which induces the
conversion of DHA into RvD1 [103]. In this sense, the rise in ROS may
induce the production of SPMs as a self-protective mechanism. In
summary, SPMs can modulate the activity of several oxidative enzymes
in cells, reducing oxidative stress and even controlling their own
synthesis.
5. Ageing, immunosenescence and control of ROS biosynthesis
Immunosenescence refers to the gradual deterioration of the im-
mune system brought on by natural age advancement. This process is
associated with chronic ROS production, mainly in phagocytic immune
cells, as senescent cells exhibit a decreased capacity to regulate their
own redox balance and autophagic capacity [94]. ΜΦs of aging mice
accumulate a large number of lipofuscin granules that appear to pro-
mote higher ROS accumulation making cells more vulnerable to oxi-
dative stress. Moreover, these senescentΜΦs show impaired phagocytic
and digestive capacity, increased expression and activity of XO and
lower levels of antioxidant enzymes, such as catalase and GSH that can
be responsible for oxidative stress [104]. Increased XO activity can
activate NLRP3, triggering the release of several pro-inflammatory cy-
tokines. Although the mechanisms by which XO is linked to the in-
flammation process are not entirely clear yet, some authors propose
that XO can activate certain TLRs in phagocytes [105]. This harmful
inflammation may be perpetuated not only by the synthesis and release
of pro-inflammatory metabolites, but also by the reduction of SPM le-
vels. In the elderly, there is a shift in arachidonic acid metabolism to-
wards the formation of pro-inflammatory eicosanoids, decreasing the
production of anti-inflammatory derivatives. Along this same line, LXA4
levels are profoundly decreased with ageing [106]. In this context,
several factors collaborate to induce the senescent damage: alteration in
cell detoxifying metabolism, increases in pro-inflammatory mediator
production, and reduction of SPMs. All of these mechanisms drive the
senescent cell inexorably to cell death.
6. Concluding remarks
Survival of ΜΦs and other myeloid cells represents a relevant issue
in the execution of their physiological and homeostatic functions. The
presence of high amounts of ROS and RNS in the inflammatory scenario
has a dual role in the survival/death balance depending on the immune
cell subset. In fact, the weak functionality of agedΜΦs has been related
to a reduced capacity to retain viability in the last steps of the activation
process resulting in impaired autophagic function in aged individuals
and a lower pro-resolutive capacity of immune cells [94,107]. There-
fore, unraveling the mechanisms of functional MΦ deterioration and
developing drugs to restore the full homeostatic and tissue repair ca-
pacity ofΜΦs based on the retention of their self-defense pathways may
result in new therapeutic interventions to treat diseases in which these
characteristic properties have been attenuated or even lost.
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